EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mitochondrial potential reflects T cell fitness and function during cancer immunotherapy

Paul L Lindau, Alex V Nesta, Caroline E Roe, Madelyn D Landis, Zaid Hatem, Allison E Sewell iD, Allison K Blount, Jackie E Bader, Reddy Anupama, W Kimryn Rathmell iD, Jonathan M Irish iD, Jeffrey C Rathmell iD und 1 weitere

The Journal of Immunology · 07.06.2026 · 215 (6)

DOI: 10.1093/jimmun/vkag120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 17.06.2026. Verfasst von Paul L Lindau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Immunotherapy, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCRR NIH HHS, NEI NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Checkpoint inhibitors have transformed cancer treatment, yet predicting responses remains challenging. Mitochondrial quality decreases in tumor infiltrating lymphocytes and correlates with impaired antitumor immunity in animal models. Mitochondrial membrane potential (MMP) increases with T cell activation and may also indicate cellular dysfunction. Here, we assessed the MMP of tumor-associated T cells as an indicator of cell phenotypes and immunotherapy responses in non-small cell lung carcinoma and clear cell renal cell carcinoma patients. Primary tumors were collected followed by analysis of peripheral blood mononuclear cells prior to and after 3 wk on treatment with immune checkpoint inhibitors (ICIs). Peripheral blood mononuclear T cells were analyzed for MMP using tetramethylrhodamine ethyl ester (TMRE) and sorted into high and low populations. TCRβ and single-cell RNA sequencing of primary tumors identified and characterized peripheral blood T cell clones associated with the tumor microenvironment. As anticipated, ICI therapy increased the frequency of effector T cells in patients who experienced clinical benefit. TMREhigh peripheral blood T cells with tumor-matching TCRβ sequences had elevated oxidative phosphorylation gene signatures. Gene signatures of stress and exhaustion, such as Tigit and Cmc1, were also elevated in the TMREhigh CD8 T cell populations, while gene expression patterns in TMRElow cells suggested mitochondrial fitness and cell longevity. Importantly, clinical benefit from ICIs was negatively correlated with the TMREhigh CD8 T cell gene expression signature. These findings highlight a T cell population characterized by elevated MMP that correlates with exhaustion-like transcriptional states and poor response to immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCarcinoma, Renal CellImmunotherapyKidney NeoplasmsLung NeoplasmsT-LymphocytesFemaleHumansMaleImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingMembrane Potential, MitochondrialMitochondriaT-Cell ExhaustionTumor Microenvironment

Stichwörter der Autor:innen

T cellscheckpoint inhibitorkidney cancerlung cancermetabolismmitochondria

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
  • Vindhya Data Science, Morrisville, NC, United States.
  • Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, United States.
  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States.
  • The James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
  • Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, United States.

ORCID-Profile: Allison E Sewell, W Kimryn Rathmell, Jonathan M Irish, Jeffrey C Rathmell

Förderung

  • NCRR NIH HHS
  • NEI NIH HHS
  • NIAMS NIH HHS
  • NCI NIH HHS
  • Ludwig Center at the University of Chicago
  • Vanderbilt Ingram Cancer Center

Zitieren

APA

Lindau, P. L., Nesta, A. V., Roe, C. E., Landis, M. D., Hatem, Z., Sewell, A. E., Blount, A. K., Bader, J. E., Anupama, R., Rathmell, W. K., Irish, J. M., Rathmell, J. C., & Beckermann, K. E. (2026). Mitochondrial potential reflects T cell fitness and function during cancer immunotherapy. The Journal of Immunology, 215(6). https://doi.org/10.1093/jimmun/vkag120

Vancouver

Lindau PL, Nesta AV, Roe CE, Landis MD, Hatem Z, Sewell AE, et al. Mitochondrial potential reflects T cell fitness and function during cancer immunotherapy. The Journal of Immunology. 2026;215(6). doi:10.1093/jimmun/vkag120

BibTeX
@article{Lindau2026,
  author = {Lindau, Paul L and Nesta, Alex V and Roe, Caroline E and Landis, Madelyn D and Hatem, Zaid and Sewell, Allison E and Blount, Allison K and Bader, Jackie E and Anupama, Reddy and Rathmell, W Kimryn and Irish, Jonathan M and Rathmell, Jeffrey C and Beckermann, Kathryn E},
  title = {Mitochondrial potential reflects T cell fitness and function during cancer immunotherapy},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {6},
  doi = {10.1093/jimmun/vkag120}
}
Kostenlos starten →